Research support

Stem cell therapy for traumatic injury on the horizon

University of Texas Health receives funding for study

Photo
Adult sensory neurons (purple) are protected from attack by activated macrophages (blue) when cultured with MultiStem (green).
Source: Athersys, Inc.

The University of Texas Health Science Center at Houston (UTHealth) has received funding through a public/private partnership for the first-ever clinical trial investigating a stem cell therapy for early treatment and prevention of complications after severe traumatic injury. The proposed Phase 2 trial is underwritten with $2 million from the Medical Technology Consortium (MTEC) and $1.5 million from Memorial Hermann Foundation. Athersys, Inc., will provide MultiStem, the investigational clinical product for the trial, and provide regulatory and operational support, as its contribution to the trial.

Traumatic injury is the leading cause of death and disability among children and members of the military, and also has a significant impact on the elderly. Following serious trauma, an acute hyperinflammatory response can be triggered, impairing recovery and leading to additional complications,” said Charles S. Cox, Jr., M.D., principal investigator, George and Cynthia Mitchell Distinguished Chair in Neurosciences at McGovern Medical School at UTHealth and co-director of the Red Duke Trauma Institute at Memorial Hermann-Texas Medical Center. “Our prior research demonstrates that administration of MultiStem following acute neurological injury can help improve recovery and reduce the occurrence or severity of certain complications, so we are excited about the clinical potential in this area.”

Following serious trauma, an acute hyperinflammatory response can be triggered, impairing recovery and leading to additional complications

Charles S. Cox

Cox and other researchers at McGovern Medical School at UTHealth have been studying MultiStem in preclinical and clinical trials as a possible therapy for traumatic brain injury and stroke for the past 10 years.

According to the Centers for Disease Control, traumatic injury is the third-leading cause of death in the US and the leading cause in Americans ages 1 to 44. Most deaths occur in the first three days from uncontrolled bleeding and traumatic brain injury, but 25 percent of deaths occur after three days from factors such as inflammatory-related complications. Those secondary complications can include acute kidney injury, acute respiratory distress syndrome, venous thromboembolic disease and swelling and tissue death after traumatic brain injury.

The proposed randomized, double-blind, placebo-controlled Phase 2 clinical trial must still go through review by the US Food and Drug Administration and approval from the UTHealth Internal Review Board, and therefore, the design is subject to additional input. Researchers hope to enroll approximately 150 severely injured trauma patients within hours of hospitalization at Memorial Hermann-TMC, the busiest Level 1 trauma center in the country.


Source: University of Texas Health Science Center at Houston

23.04.2018

Read all latest stories

Related articles

"WAKE-UP"

Study provides new treatment option for stroke patients

In an international study, scientists of the University Medical Center Hamburg-Eppendorf (UKE) have discovered a new therapeutic option for a large group of stroke patients. The main results of the…

Immunotherapy

Promising vaccine suppresses peanut allergies in mice

A vaccine may successfully turn off peanut allergy in mice, a new study shows. Just three monthly doses of a nasal vaccine protected the mice from allergic reactions upon exposure to peanut,…

Power of the heart

Gene therapy can make the heart stop atrial fibrillation itself

The heart is capable of terminating arrhythmias itself after local gene therapy, potentially avoiding the need for patients to undergo painful electric shocks, according to a proof-of-concept study…

Related products

Research use only (RUO)

Eppendorf - Mastercycler nexus X2

Eppendorf AG

Research use only (RUO)

SARSTEDT - Low DNA Binding Micro Tubes

SARSTEDT AG & CO.

Research use only (RUO)

Shimadzu - CLAM-2000

Shimadzu Europa GmbH